Welcome to LookChem.com Sign In|Join Free

CAS

  • or

101711-55-1

Post Buying Request

101711-55-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

101711-55-1 Usage

Description

2-(tert-butyldiMethylsilyloxy)ethanaMine, also known as a silyl ether protecting group, is a chemical compound derived from ethanolamine with a tert-butyldimethylsilyloxy (TBDMS) group attached to the 2-position. It is characterized by its light brown liquid appearance and is commonly used in organic synthesis to protect alcohols and amines from unwanted reactions.

Uses

Used in Organic Synthesis:
2-(tert-butyldiMethylsilyloxy)ethanaMine is used as a protecting group for alcohols and amines during organic synthesis. The TBDMS group can be selectively introduced and removed under mild conditions, allowing chemists to control the reactivity of these functional groups and prevent unwanted side reactions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(tert-butyldiMethylsilyloxy)ethanaMine is used as an intermediate in the synthesis of various drug molecules. Its ability to protect alcohols and amines makes it a valuable tool in the development of complex molecular structures with specific biological activities.
Used in the Preparation of 3-substituted Androsterone Derivatives:
2-(tert-butyldiMethylsilyloxy)ethanaMine is specifically used in the preparation of 3-substituted androsterone derivatives, which are important compounds in the field of steroid chemistry. These derivatives have potential applications in the development of new drugs targeting hormonal disorders and other related conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 101711-55-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,7,1 and 1 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 101711-55:
(8*1)+(7*0)+(6*1)+(5*7)+(4*1)+(3*1)+(2*5)+(1*5)=71
71 % 10 = 1
So 101711-55-1 is a valid CAS Registry Number.

101711-55-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[tert-butyl(dimethyl)silyl]oxyethanamine

1.2 Other means of identification

Product number -
Other names Ethanamine,mono-TMS

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:101711-55-1 SDS

101711-55-1Relevant articles and documents

Discovery and Characterization of a Peptoid with Antifungal Activity against Cryptococcus neoformans

Corson, Ashley E.,Armstrong, Scott A.,Wright, Matthew E.,McClelland, Erin E.,Bicker, Kevin L.

, p. 1139 - 1144 (2016)

Studies show there is an increasing rate of fungal infections, especially in immunocompromised patients and treatments for fungal genera, such as Aspergillus, Candida, and Cryptococcus, carry significant cytotoxicity with an increasing prevalence of antifungal resistance. We have previously reported a high-throughput assay for identifying peptoids with antimicrobial properties from combinatorial libraries. Here we report the application of this assay in identifying a peptoid with antifungal properties against Cryptococcus neoformans. Termed AEC5, this peptoid has comparable potency to existing clinical antifungal agents, excellent stability, and minimal cytotoxicity in mammalian cells.

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers

Bonnet, Muriel,Hong, Cho Rong,Gu, Yongchuan,Anderson, Robert F.,Wilson, William R.,Pruijn, Frederik B.,Wang, Jingli,Hicks, Kevin O.,Hay, Michael P.

, p. 2123 - 2132 (2014)

A novel class of nitroimidazole alkylsulfonamides have been prepared and evaluated as hypoxia-selective cytotoxins and radiosensitisers. The sulfonamide side chain markedly influences the physicochemical properties of the analogues: lowering aqueous solubility and raising the electron affinity of the nitroimidazole group. The addition of hydroxyl or basic amine groups increased aqueous solubility, with charged amine groups contributing to increased electron affinity. The analogues covered the range of electron affinity for effective radiosensitisation with one-electron reduction potentials ranging from -503 to -342 mV. Cytotoxicity under normoxia or anoxia against a panel of human tumour cell lines was determined using a proliferation assay. 2-Nitroimidazole sulfonamides displayed significant hypoxia-selective cytotoxicity (6 to 64-fold), while 4- and 5-nitroimidazole analogues did not display hypoxia-selective cytotoxicity. All analogues sensitised anoxic HCT-116 human colorectal cells to radiation at non-toxic concentrations. 2-Nitroimidazole analogues provided modest sensitisation due to the relatively low concentrations used while several 5-nitroimidazole analogues provided equivalent sensitisation to misonidazole and etanidazole at similar molar concentrations.

Bioactive 4-Oxoheptanedioic Monoamide Derivatives of Proteins and Ethanolaminephospholipids: Products of Docosahexaenoate Oxidation

Guo, Junhong,Hong, Li,West, Xiaoxia Z.,Wang, Hua,Salomon, Robert G.

, p. 1706 - 1719 (2016)

Oxidative stress causes lipid-derived oxidative modification of biomolecules that has been implicated in many pathological states. Phospholipids containing polyunsaturated fatty acids are major targets of free radical-initiated oxidation. Phospholipids that incorporate docosahexaenoate (DHA) are highly enriched in important neural structures including the brain and retina, where DHA comprises 40% and 60% of total fatty acids, respectively. Oxidative fragmentation of 2-docosahexaenoyl-1-palmityl-sn-glycerophosphocholine generates esters of 4-hydroxy-7-oxohept-5-enoic acid (HOHA) and 4-keto-7-oxohept-5-enoic acid (KOHA) with 2-lysophosphatidylcholine, HOHA-PC, and KOHA-PC. Covalent HOHA adducts that incorporate the primary amino groups of proteins and ethanolamine phospholipids in carboxyethylpyrrole (CEP) derivatives were detected immunologically with anti-CEP antibodies in human tumors, retina, and blood. Now, we generated an anti-OHdiA antibody to test the hypothesis that KOHA adducts, which incorporate the primary amino groups of proteins or ethanolamine phospholipids in 4-oxo-heptanedioic (OHdiA) monoamide derivatives, are present in vivo. However, whereas the anti-CEP antibody is highly specific and does not cross-react with the OHdiA monoamide epitope, the anti-OHdiA monoamide antibody cross-reacted with CEP epitopes making it of little value as an analytical tool for OHdiA monoamides but suggesting the possibility that OHdiA monoamides would exhibit receptor-mediated biological activity similar to that of CEP. An LC-MS/MS method was developed that allows quantification of OHdiA derivatives in biological samples. We now find that KOHA-PC forms OHdiA monoamide adducts of proteins and ethanolamine phospholipids and that OHdiA-protein levels are significantly higher than OHdiA-ethanloamine phospholipid levels in blood from healthy human subjects, 0.45 μM and 0.18 μM, respectively (n = 3, and p = 0.027). OHdiA monoamide epitopes are angiogenic, causing TLR2-dependent adhesion and tube formation by human umbilical vein endothelial cells. OHdiA monoamide epitopes are only slightly less potent than CEP epitopes that contribute to the pathological angiogenesis of age-related macular degeneration and tumor growth.

Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids

Tanimoto, Shuho,Sakai, Satoshi,Kudo, Eriko,Okada, Seiji,Matsumura, Shuichi,Takahashi, Daisuke,Toshima, Kazunobu

, p. 911 - 914 (2012)

Sweet degradation: A designed fullerene-sugar hybrid selectively caused the degradation of HIV-1 protease, an important target of anti-HIV therapy. Degradation was achieved at irradiation with long-wavelength UV (365 nm) or visible light (diffuse sunlight) in the absence of any additives and under neutral conditions. Moreover, the hybrid inhibited HIV-1 replication in living cells infected with HIV-1.

Introduction of mercaptoethyl at sorafenib pyridine‐2‐amide motif as a potentially effective chain to further get sorafenib‐PEg‐DGL

Chen, Ying,Kuerbana, Kudelaidi,Wan, Qi,Wang, Ke,Ye, Li,Yu, Zhihui

, (2020/02/11)

The crystal structure of the sorafenib and B‐RAF complex indicates that the binding cavity occupied by the pyridine‐2‐carboxamide in sorafenib has a large variable space, making it a reasonable modification site. In order to identify novel compounds with anti‐cancer activity, better safety and polar groups for further application, five sorafenib analogs with new pyridine‐2‐amide side chains were designed and synthesized. Preliminary pharmacologic studies showed that these compounds displayed much lower toxicities than that of sorafenib. Among them, compound 10b bearing mercaptoethyl group kept relevant antiproliferation potency compared to sorafenib in Huh7 and Hela cell lines with values of IC50 58.79 and 63.67 μM, respectively. As a small molecule inhibitor targeting protein tyrosine kinases, thiol in compound 10b would be an active group to react with maleimide in a mild condition for forming nanoparticles Sorafenib‐PEG‐DGL, which could be developed as a delivery vehicle to improve the concentration of anti‐tumor therapeutic agents in the target cancer tissue and reduce side effects in the next study.

Route exploration and synthesis of the reported pyridone-based PDI inhibitor STK076545

Dockendorff, Chris,Flaumenhaft, Robert,Greve, Eric,Lin, Lin,Lindeman, Sergey V.,Scartelli, Christina

, p. 6665 - 6681 (2020/09/21)

The enzyme protein disulfide isomerase (PDI) is essential for the correct folding of proteins and the activation of certain cell surface receptors, and is a promising target for the treatment of cancer and thrombotic conditions. A previous high-throughput screen identified the commercial compound STK076545 as a promising PDI inhibitor. To confirm its activity and support further biological studies, a resynthesis was pursued of the reported β-keto-amide with an N-alkylated pyridone at the α-position. Numerous conventional approaches were complicated by undesired fragmentations or rearrangements. However, a successful 5-step synthetic route was achieved using an aldol reaction with an α-pyridone allyl ester as a key step. An X-ray crystal structure of the final compound confirmed that the reported structure of STK076545 was achieved, however its lack of PDI activity and inconsistent spectral data suggest that the commercial structure was misassigned.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 101711-55-1